药物对比
Dapagliflozin vs Troglitazone
Dapagliflozin 与 Troglitazone 对比：SGLT2抑制剂与已撤市的TZD。比较口服糖尿病药物的疗效、肝毒性风险及目前的可获得性。
此页面暂无可用的对比维度。
临床背景
This comparison typically occurs when reviewing discontinued historical TZDs versus modern SGLT2 inhibitors for type 2 diabetes management.
结论
Dapagliflozin is an available evidence-based therapy while Troglitazone is obsolete due to severe hepatotoxicity.
全部药物对比